Sir,

An acute or hyper-acute rejection in any solid organ transplant is due to the presence of preformed anti-HLA antibodies.\[[@ref1]\] These antibodies can be identified with cell-based assays; Complement-dependent Lympho-Cytotoxicity Crossmatch (CDCXM) and Flow Cytometry crossmatch (FCXM) and bead-based assays; Panel Reacting Antibodies (PRA) and Single Antigen Bead (SAB).\[[@ref2]\] Using cell-based and bead-based assays in an algorithmic manner combines relative merits of each assay to our advantage and allows better interpretation of results. Routinely, in a pre-renal transplant work-up, commonest scenarios are where cell-based crossmatch and SAB are concordant, either negative or positive. We present a case that belongs to a third scenario, an unusual presentation, where CDCXM and FCXM were negative; SAB was positive and virtual crossmatch revealed Donor Specific Antibody (DSA).

A 25-year-old male patient suffering from end-stage renal disease was referred to our laboratory by the nephrologist for pre-transplant workup with his wife as prospective donor. As per the institutional protocol, low resolution HLA typing for class I (A and B) and class II (DR) antigens {polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP)} was performed for assessing relationship as a pre-requisite according to The Human Organ Transplant Act, India, 1994 and its amendments.\[[@ref3]\] Anti-HLA antibody detection was negative by CDCXM and FCXM. CDCXM was performed using the standard National Institute of Health (NIH) technique and FCXM was performed for T-cell and B-cell on BD FACSVerse™ Flow cytometer (San Jose, CA, USA). Since the patient had history of blood transfusion, PRA was performed using Flow PRA Class I & II Screening Test kit (One Lambda, Inc., CA, USA) and it was found positive. As this scenario presented a discrepancy between cell-based and bead-based methods, repeat testing were done to rule out any technical errors. However, results remained the same. Decision was taken to perform SAB assay (LIFECODES LSA™ Kit, Immucor Transplant Diagnostics Inc., USA) on Luminex platform. SAB assay was positive for class I antibodies and negative for class II antibodies. Antibodies were identified against HLA-A\*24:03 (MFI-11531) and HLA-A\*24:02 (MFI-5252). Low resolution typing identified donor HLA-A allele as A\*24 only. Therefore, high resolution typing for donor HLA-A locus was also done to identify complete antigen. High resolution typing revealed HLA-A\*24:03 in donor and confirmed the presence of DSA.

To further understand and resolve this uncommon discrepancy between cell-based crossmatch and SAB, literature was reviewed.\[[@ref4]\] Of all the possible mentioned reasons for such discordance, performing tests to negate pro-zone and post-zone phenomenon was undertaken and FCXM was repeated with dilutions of recipient\'s serum and donor\'s cells (dilutions 1:2 to 1:8). FCXM was found to be positive for T cells (median channel shift was 59; cut-off ≥26) and negative for B cells (median channel shift was 98; cut-off ≥110) with donor cells in 1:2 dilutions \[[Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}\]. This positive result for T-cell FCXM corroborated with SAB results and resolved the discrepancy.

###### 

Brief Case Illustration

               HLA typing                Results          CDC        FCXM              SAB (donor specific antibody)                                                                                      
  ------------ ------------------------- ---------------- ---------- ----------------- ------------------------------- ---------- ---------- ---------- ---------------------- ---------- --------------- -------
  Case         Recipient                 A11,68           B52,52     DR04,14           Initial                         Negative   Negative   Negative   AllelesHLA-A\* 24:03   MFI11531   AllelesNo DSA   MFINA
  Age/Gender   Sensitization                                                                                                                                                                              
  25/M         Yes (blood transfusion)                                                                                                                                                                    
  Donor        A03,24                    B55,55           DR11,14    Serum dilutions   Negative                        Negative   Negative                                                                
  Age/Gender   Relationship                                                                                                                                                                               
  26/F         Wife                      Cell dilutions   Negative   Positive          Negative                                                                                                           

CDC=Complement Dependent Cytotoxicity Crossmatch, FCXM=Flow Cytometry based Crossmatch, DSA=Donor Specific Antibodies

![Flow Cytometry Crossmatch results at different serum and cell dilutions](IJN-30-55-g001){#F1}

All tests, CDCXM, FCXM, PRA, and SAB, are used to detect the presence of donor-specific anti-HLA antibodies (DSA) in the recipient and in most of the cases, results of all tests are in concordance. However, rarely there can be discordance. Literature review identified following reasons for discordance: Pro-zone/Post-zone effect, stability of antigens, antibody against denatured antigens v/s native antigen and allelic expression on the donor cell surface.

In the present case, post-zone phenomenon was responsible for the discordance between results of cell-based and bead-based assays. Excess of antigen inhibits lattice formation and subsequent agglutination between antigen-antibody may not occur, which can give false-negative results. Diluting the donor cells or increasing the serum-to-cell ratio can solve the problem.

The case also highlights the importance of performing cell-based and bead-based assay, in an algorithmic manner, in a pre-transplant work-up to rule-out any donor specific antibodies, especially if the recipient has history of any sensitizing event. It can be concluded that in these cases where cell-based assays results are discordant with the SAB assay results, post-zone effect should also be considered to confirm or rule out DSA.
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